I. Diakité

Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States

Rongzhe Liu, Olalekan O. Oluwole, I. Diakité et al. · Journal of Medical Economics · 2021 · 35 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +16

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective

Adnan Alsumali, Laurence Djatche, Andrew Briggs et al. · PharmacoEconomics · 2021 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Risk factors for surgical site infection in children at the teaching hospital Gabriel Touré, Bamako

A Togo, Y Coulibaly, B T Dembéle et al. · Journal of Hospital Infection · 2011 · 19 citations

Medicine, Pediatrics, Surgery +16

Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US

Olalekan O. Oluwole, Rongzhe Liu, I. Diakité et al. · Journal of Medical Economics · 2022 · 17 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases

I. Diakité, Sylvi Nguyen, Ugne Sabale et al. · Journal of Medical Economics · 2023 · 15 citations · Full text

Veterinary Medicine, Pharmacoeconomics, Preventive Medicine +17